Consequences in women of participating in a study of the natural history of cervical intraepithelial neoplasia 3
- PMID: 20716265
- DOI: 10.1111/j.1479-828X.2010.01170.x
Consequences in women of participating in a study of the natural history of cervical intraepithelial neoplasia 3
Abstract
Background: A retrospective cohort study was performed in 1063 women diagnosed with cervical intraepithelial neoplasia grade 3 (CIN3) (previously termed carcinoma in situ- CIS) in the National Women's Hospital, Auckland, New Zealand. The study describes the clinical management and outcomes for women with CIN3 diagnosed in the decade of 1965-1974, when treatment with curative intent was withheld in an unethical clinical study of the natural history of CIS. A comparison is made with women who were diagnosed earlier (1955-1964) and later (1975-1976).
Aims: The aim of the study is to record the medical encounters, frequency and management of cytological abnormalities and the occurrence of invasive cancers. The medical records, cytology and histopathology were reviewed and data linked with cancer and death registers.
Results: Women diagnosed with CIN3 in 1965-1974 (n = 422), compared with those diagnosed earlier (n = 385) or later (n = 256): (i) were less likely to have initial treatment with curative intent (51% vs 95 and 85%, respectively); (ii) had more follow-up biopsies (P < 0.0005); (iii) were more likely to have positive cytology during follow-up (P < 0.005) and positive smears that were not followed within six months by a treatment with curative intent (P < 0.005); and (iv) experienced a higher risk of cancer of the cervix or vaginal vault (RR = 3.3 compared with the first period, 95% CI: 1.7-5.3). Among women diagnosed in 1965-1974, those initially managed by punch or wedge biopsy alone had a cancer risk ten times (95% CI: 3.9-25.7) higher than women initially treated with curative intent.
Conclusions: During the 'clinical study' (1965-1974), women underwent numerous interventions that were aimed to observe rather than treat their condition, and their risk of cancer was substantially increased.
Comment in
-
The 1987 National Women's Hospital 'Unfortunate experiment'.Aust N Z J Obstet Gynaecol. 2011 Apr;51(2):184; author reply 185-6. doi: 10.1111/j.1479-828X.2011.01290.x. Aust N Z J Obstet Gynaecol. 2011. PMID: 21466525 No abstract available.
-
Re: Consequences in women of participating in a study of the natural history of cervical intraepithelial neoplasia 3.Aust N Z J Obstet Gynaecol. 2011 Apr;51(2):186-7; author reply 187. doi: 10.1111/j.1479-828X.2011.01305.x. Aust N Z J Obstet Gynaecol. 2011. PMID: 21466527 No abstract available.
Similar articles
-
Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study.Lancet Oncol. 2008 May;9(5):425-34. doi: 10.1016/S1470-2045(08)70103-7. Epub 2008 Apr 11. Lancet Oncol. 2008. PMID: 18407790
-
Outcomes for women without conventional treatment for stage 1A (microinvasive) carcinoma of the cervix.Aust N Z J Obstet Gynaecol. 2018 Jun;58(3):321-329. doi: 10.1111/ajo.12753. Epub 2018 Feb 6. Aust N Z J Obstet Gynaecol. 2018. PMID: 29405269
-
Heterogeneity in CIN3 diagnosis.Lancet Oncol. 2008 May;9(5):404-6. doi: 10.1016/S1470-2045(08)70110-4. Lancet Oncol. 2008. PMID: 18452848 No abstract available.
-
Predicting regression of cervical intraepithelial neoplasia grade 2 in women under 25 years.Am J Obstet Gynecol. 2022 Feb;226(2):222.e1-222.e13. doi: 10.1016/j.ajog.2021.09.009. Epub 2021 Sep 14. Am J Obstet Gynecol. 2022. PMID: 34534506
-
[Management of CIN1].J Gynecol Obstet Biol Reprod (Paris). 2008 Feb;37 Suppl 1:S114-20. doi: 10.1016/j.jgyn.2007.11.017. Epub 2008 Jan 10. J Gynecol Obstet Biol Reprod (Paris). 2008. PMID: 18191500 Review. French.
Cited by
-
Are CIN3 risk or CIN3+ risk measures reliable surrogates for invasive cervical cancer risk?J Am Soc Cytopathol. 2020 Nov-Dec;9(6):602-606. doi: 10.1016/j.jasc.2020.07.133. Epub 2020 Jul 29. J Am Soc Cytopathol. 2020. PMID: 32839150 Free PMC article.
-
Cervical cancer prevention and control in women living with human immunodeficiency virus.CA Cancer J Clin. 2021 Nov;71(6):505-526. doi: 10.3322/caac.21696. Epub 2021 Sep 9. CA Cancer J Clin. 2021. PMID: 34499351 Free PMC article. Review.
-
Correcting Error in Academic Publishing: An Ethical Responsibility.J Bioeth Inq. 2015 Dec;12(4):665-73. doi: 10.1007/s11673-015-9644-6. Epub 2015 Jul 15. J Bioeth Inq. 2015. PMID: 26173775
-
Screening of Precancerous Lesions in Women with Human Papillomavirus (HPV) Infection by Molecular Typing and MicroRNA Analysis.J Pers Med. 2023 Mar 15;13(3):531. doi: 10.3390/jpm13030531. J Pers Med. 2023. PMID: 36983713 Free PMC article.
-
The Role of microRNA Expression and DNA Methylation in HPV-Related Cervical Cancer: A Systematic Review.Int J Mol Sci. 2024 Nov 26;25(23):12714. doi: 10.3390/ijms252312714. Int J Mol Sci. 2024. PMID: 39684425 Free PMC article.